Home/Filings/4/A/0001209191-14-070288
4/A//SEC Filing

Horizon Pharma plc 4/A

Accession 0001209191-14-070288

CIK 0001492426operating

Filed

Nov 19, 7:00 PM ET

Accepted

Nov 20, 1:11 PM ET

Size

6.5 KB

Accession

0001209191-14-070288

Insider Transaction Report

Form 4/AAmended
Period: 2014-11-13
Transactions
  • Sale

    Ordinary shares, nominal value $0.0001 per share

    2014-11-13$11.54/sh2,000,000$23,080,000214,836 total
Footnotes (2)
  • [F1]This Form 4/A amends that certain Form 4 filed by the Reporting Person on November 17, 2014. On November 13, 2014, Dr. Nohria agreed to sell 1,739,130 ordinary shares pursuant to that certain Underwriting Agreement, dated as of November 13, 2014 (the "Underwriting Agreement"), among the Issuer, the several selling shareholders (the "Selling Shareholders") named in Schedule I to the Underwriting Agreement and Morgan Stanley & Co. LLC, Citigroup Global Markets Inc., Cowen and Company, LLC and Jefferies LLC, as representatives of the several underwriters (the "Underwriters") named in Schedule II to the Underwriting Agreement. Dr. Nohria also granted the Underwriters the option to purchase an additional 260,870 ordinary shares. On November 18, 2014, the Underwriters exercised their option to purchase the additional ordinary shares. The numbers in the table above have been amended to relect the exercise by the Underwriters of their option to purchase additional shares.
  • [F2](continued from footnote 1) The price to the public was $12.05 per ordinary share and the proceeds to Dr. Nohria was $11.537875 per ordinary share. In addition, in connection with the sale of ordinary shares, the Issuer also paid an aggregate of $2,564,766 to Altiva Capital, LLC, Dr. Nohria and Mohun Patrick Nohria 2013 Gift Trust (the "Reimbursed Shareholders") in connection with the sale of the ordinary shares by such Reimbursed Shareholders pursuant to the Underwriting Agreement, each Reimbursed Shareholder to receive its pro rata amount based on the number of shares to be sold by such Reimbursed Shareholder (or $0.262125 per share).

Issuer

Horizon Pharma plc

CIK 0001492426

Entity typeoperating
IncorporatedIreland

Related Parties

1
  • filerCIK 0001492426

Filing Metadata

Form type
4/A
Filed
Nov 19, 7:00 PM ET
Accepted
Nov 20, 1:11 PM ET
Size
6.5 KB